Evidence-Based Pharmaceutical Care in Community Pharmacies: A Survey of 595 French Pharmacists
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rousseau, M.-C.; Bardet, J.-D.; Bellet, B.; Allenet, B. Comment la Pharmacie Clinique est-elle perçue par les pharmaciens d’officine ? « c’est mettre le patient au centre de l’activité, s’intéresser à son environnement, savoir comment il vit. C’est intégrer tout cela, bien au-delà du simple médicament. ». Le Pharm. Hosp. Clin. 2020, 55, 377–390. [Google Scholar] [CrossRef]
- Allemann, S.S.; van Mil, J.W.F.; Botermann, L.; Berger, K.; Griese, N.; Hersberger, K.E. Pharmaceutical Care: The PCNE definition 2013. Int. J. Clin. Pharm. 2014, 36, 544–555. [Google Scholar] [CrossRef] [PubMed]
- Allenet, B. Let’s endorse the international terms: Go for pharmaceutical care! Pharm. Hosp. Clin. 2021, 56, 227–228. [Google Scholar]
- de Barra, M.; Scott, C.L.; Scott, N.W.; Johnston, M.; de Bruin, M.; Nkansah, N.; Bond, C.M.; Matheson, C.I.; Rackow, P.; Williams, A.J.; et al. Pharmacist services for non-hospitalised patients. Cochrane Database Syst. Rev. 2018, 9, CD013102. Available online: http://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013102/abstract (accessed on 23 July 2019). [CrossRef] [PubMed]
- Kwan, D.; Boon, H.S.; Hirschkorn, K.; Welsh, S.; Jurgens, T.; Eccott, L.; Heschuk, S.; Griener, G.G.; Cohen-Kohler, J.C. Exploring consumer and pharmacist views on the professional role of the pharmacist with respect to natural health products: A study of focus groups. BMC Complement. Altern. Med. 2008, 8, 40. [Google Scholar] [CrossRef] [PubMed]
- Lee, S. Amazing Fantasy #15; Marvel Comics: New York, NY, USA, 1962. [Google Scholar]
- Hepler, C.D.; Strand, L.M. Opportunities and responsibilities in pharmaceutical care. Am. J. Health Pharm. 1990, 47, 533–543. [Google Scholar] [CrossRef]
- Moullin, J.C.; Sabater-Hernández, D.; Fernandez-Llimos, F.; Benrimoj, S.I. Defining professional pharmacy services in community pharmacy. Res. Soc. Adm. Pharm. 2013, 9, 989–995. [Google Scholar] [CrossRef]
- O’Donnell, C.A. Attitudes and knowledge of primary care professionals towards evidence-based practice: A postal survey. J. Evaluation Clin. Pract. 2004, 10, 197–205. [Google Scholar] [CrossRef]
- Burkiewicz, J.S.; Zgarrick, D.P. Evidence-Based Practice by Pharmacists: Utilization and Barriers. Ann. Pharmacother. 2005, 39, 1214–1219. [Google Scholar] [CrossRef]
- Hanna, L.-A.; Hughes, C. The influence of evidence-based medicine training on decision-making in relation to over-the-counter medicines: A qualitative study. Int. J. Pharm. Pract. 2012, 20, 358–366. [Google Scholar] [CrossRef]
- McKee, P.; Hughes, C.; Hanna, L.-A. Views of pharmacy graduates and pharmacist tutors on evidence-based practice in relation to over-the-counter consultations: A qualitative study. J. Eval. Clin. Pract. 2014, 21, 1040–1046. [Google Scholar] [CrossRef]
- Rutter, P.; Wadesango, E. Does evidence drive pharmacist over-the-counter product recommendations? J. Eval. Clin. Pract. 2014, 20, 425–428. [Google Scholar] [CrossRef] [PubMed]
- Castelino, R.L.; Bajorek, B.V.; Chen, T.F. Are interventions recommended by pharmacists during Home Medicines Review evi-dence-based? J. Eval. Clin. Pract. 2011, 17, 104–110. [Google Scholar] [CrossRef] [PubMed]
- Hanna, L.-A.; Hughes, C.M. Pharmacists’ attitudes towards an evidence-based approach for over-the-counter medication. Int. J. Clin. Pharm. 2012, 34, 63–71. [Google Scholar] [CrossRef] [PubMed]
- de Sousa, I.C.; de Lima David, J.P.; Noblat, L.d.A.C.B. A drug information center module to train pharmacy students in evi-dence-based practice. Am. J. Pharm. Educ. 2013, 77, 80. [Google Scholar] [CrossRef] [PubMed]
- Aranda, J.P.; Davies, M.L.; Jackevicius, C.A. Student pharmacists’ performance and perceptions on an evidence-based medicine objective structured clinical examination. Curr. Pharm. Teach. Learn. 2019, 11, 302–308. [Google Scholar] [CrossRef] [PubMed]
- Watson, M.; Bond, C.; Grimshaw, J.; Mollison, J.; Ludbrook, A.; Walker, A. Educational strategies to promote evidence-based community pharmacy practice: A cluster randomized controlled trial (RCT). Fam. Pract. 2002, 19, 529–536. [Google Scholar] [CrossRef] [PubMed]
- Gilson, A.M.; Xiong, K.Z.; Stone, J.A.; Jacobson, N.; Chui, M.A. A pharmacy-based intervention to improve safe over-the-counter medication use in older adults. Res. Soc. Adm. Pharm. 2020, 17, 578–587. [Google Scholar] [CrossRef]
- Prescrire. Homéopathie: Toujours pas de Preuve d’éfficacité. [Homeopathy: Still no Proof of Effectiveness]. Rev. Prescrire 2012, 32, 446. Available online: https://www.prscrire.org/Fr/3/31/47896/0/NewsDetails.aspx (accessed on 6 June 2023).
- Ernst, E. Homeopathy: What does the “best” evidence tell us? Med. J. Aust. 2010, 192, 458–460. [Google Scholar] [CrossRef]
- Demicheli, V.; Jefferson, T.; Di Pietrantonj, C.; Ferroni, E.; Thorning, S.; Thomas, R.; Rivetti, A. Vaccines for preventing seasonal influenza and its complications in people aged 65 or older|Cochrane. Cochrane Syst. Rev. 2018, 2, CD004876. Available online: https://www.cochrane.org/CD004876/ARI_vaccines-preventing-seasonal-influenza-and-its-complications-people-aged-65-or-older. (accessed on 1 February 2018).
- Ng, Q.X.; Venkatanarayanan, N.; Ho, C.Y.X. Clinical use of Hypericum perforatum (St John’s wort) in depression: A meta-analysis. J. Affect. Disord. 2017, 210, 211–221. [Google Scholar] [CrossRef] [PubMed]
- Linde, K.; Berner, M.; Kriston, L. St. John’s Wort for Major Depression. Cochrane Syst. Rev. 2008, 2008, CD000448. Available online: https://www.cochrane.org/CD000448/DEPRESSN_st.-johns-wort-for-treating-depression (accessed on 30 August 2018). [CrossRef] [PubMed]
- Prescrire. Millepertuis et États Dépressifs. [St. John’s Wort and Depression]. Rev. Prescrire. 2004, 24, 362–369. Available online: https://www.prescrire.org/aLaUne/dossierMillepertuis.php (accessed on 6 June 2023).
- ANSES. Avis de l’Agence Nationale de Sécurité Sanitaire de L’alimentation, de L’environnement et du Travail” Relatif aux Risques Liés à la Présence de «Levure de riz Rouge» dans les Compléments Alimentaires. [Opinion of the National Agency for Food, Environmental and Occupational Health Safety” Relating to the Risks Associated with the Presence of “Red Yeast Rice” in food Supplements]; Report No. 2012-SA-0228; ANSES: Maison-Alfort, France, 2014; pp. 1–34. [Google Scholar]
- Klimek, M.; Wang, S.; Ogunkanmi, A. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. Pharm. Ther. 2009, 34, 313–327. [Google Scholar]
- Swissmedic. La Commercialisation de Préparations à Base de Monascus Purpureus (Levure de riz Rouge) est Illicite en Suisse. [The Marketing of Preparations Based on Monascus purpureus (Red Yeast Rice) Is Illegal in Switzerland]; Swissmedic: Bern, Switzerland, 2012; pp. 1–4. [Google Scholar]
- Prescrire. Levure de riz rouge. [Red rice yeast]. Rev. Prescrire. 2015, 35, 18. [Google Scholar]
- Solomon, D.H. Nonselective NSAIDs: Adverse cardiovascular effects. UpTodate 2022. 24 Maech. Available online: https://www.uptodate.com/contents/nsaids-adverse-cardiovascular-effects#H92624237 (accessed on 6 June 2023).
- Prescrire. AINS et Troubles Cardiovasculaires Graves: Surtout les Coxibs et le Diclofénac. [NSAIDs and Serious Cardiovascular Disorders: Especially Coxibs and Diclofenac]. Rev. Prescrire. 2015, 35, 348–350. Available online: https://www.prcrire.org/Fr/3/31/51192/0/NewsDetails.aspx (accessed on 6 June 2023).
- Ong, Y.C.; Aziz, Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. J. Clin. Pharm. Ther. 2016, 41, 170–179. [Google Scholar] [CrossRef]
- Dujovne, C.A. Red Yeast Rice Preparations: Are They Suitable Substitutions for Statins? Am. J. Med. 2017, 130, 1148–1150. [Google Scholar] [CrossRef]
- Mamiya, K.T.; Takahashi, K.; Iwasaki, T.; Irie, T. Japanese Pharmacists’ Perceptions of Self-Development Skills and Continuing Professional Development. Pharmacy 2023, 11, 73. [Google Scholar] [CrossRef] [PubMed]
- Whitfield, K.; Coombes, I.; Denaro, C.; Donovan, P. Medication Utilisation Program, Quality Improvement and Research Pharmacist—Implementation Strategies and Preliminary Findings. Pharmacy 2021, 9, 182. [Google Scholar] [CrossRef] [PubMed]
- Coomarasamy, A.; Khan, K.S. What is the evidence that postgraduate teaching in evidence based medicine changes anything? A systematic review. BMJ 2004, 329, 1017. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Respondents to Survey (Total = 595) | Registered CPs in France (N = 53,975) | p-Value |
---|---|---|---|
Male, n (%) | 196 (32.9%) | 16875 (31.3%) | 0.378 |
Mean age, years (SD) | 38.2 (11.7) | 46.2 | <0.01 |
Age band, n (%) | |||
<30 years | 193 (32.4%) | ||
30–39 years | 167 (28.1%) | ||
40–49 years | 105 (17.6%) | ||
≥50 years | 130 (21.8%) | ||
Pharmacist’s status, n (%) | |||
Pharmacy owner CP | 330 (55.5%) | 25,189 (46.7%) | <0.01 |
Salaried CP | 176 (29.6%) | ||
Substitute CP | 30 (5.0%) | ||
Junior CP or final year student | 59 (9.9%) | ||
Pharmacy location, n (%) | |||
City centre | 128 (21.5%) | ||
Urban area | 73 (12.3%) | ||
Social housing estate | 38 (6.4%) | ||
Rural area | 216 (36.3%) | ||
Suburban area | 140 (23.5%) | ||
Regions of France with most responders, n (%) | |||
Provence and Cote d’Azur (Mediterranean SE of France) | 88 (14.8%) | 4480 (8.3%) | <0.01 |
Auvergne Rhone Alpes (SE France) | 76 (12.8%) | 6821 (12.6%) | 0.921 |
Aquitaine (SW France) | 67 (11.3%) | 5375 (10%) | 0.289 |
Loire valley (central France) | 59 (9.9%) | 2150 (4%) | <0.01 |
South of France | 54 (9.1%) | 4650 (8.6%) | 0.689 |
Case | Type of Response | N = 595 | Points |
---|---|---|---|
EBP response with action | 479 (80.5%) | 4 | |
EBP response without action | 35 (5.9%) | 3 | |
Did not know | 8 (1.3%) | 2 | |
Not EBP | 73 (12.3%) | 1 | |
3 | Red yeast rice as a substitute for statins, n (%) | ||
EBP response with action | 278 (46.7%) | 4 | |
EBP response without action | 26 (4.4%) | 3 | |
Did not know | 25 (4.2%) | 2 | |
Not EBP | 266 (44.7%) | 1 | |
4 | Choice of NSAID, n (%) | ||
EBP response | 149 (25.0%) | 4 | |
Did not know | 196 (32.9%) | 2 | |
Not EBP | 250 (42.0%) | 1 |
Junior CP (n = 59) | Salaried CP (n = 176) | Substitute CP (n = 30) | Owner CP (n = 330) | p | All (n = 595) | |
---|---|---|---|---|---|---|
Professional journals 1 | 46 (78.0%) | 138 (78.4%) | 23 (76.7%) | 182 (55.2%) | <0.01 | 389 (65.4%) |
Pharmaceutical industry information 2 | 41 (69.5%) | 140 (79.5%) | 17 (56.7%) | 188 (57.0%) | <0.01 | 386 (64.9%) |
Conferences 3 | 21 (35.6%) | 99 (56.3%) | 10 (33.3%) | 223 (67.6%) | <0.01 | 353 (59.3%) |
University 4 courses | 28 (47.5%) | 75 (42.6%) | 19 (63.3%) | 105 (31.8%) | <0.01 | 227 (38.2%) |
Personal contacts 5 | 26 (44.1%) | 42 (23.9%) | 10 (33.3%) | 80 (24.2%) | <0.01 | 158 (26.6%) |
Reading “La revue Prescrire” 6 | 15 (25.4%) | 34 (19.3%) | 6 (20.0%) | 63 (19.1%) | 0.73 | 118 (19.8%) |
A. Sources (Used More than 50% of the Time) on Homeopathic and Herbal Medicines * | N = 595 |
---|---|
Handbooks for both pharmacists and the general public | 291 (48.9%) |
Summary of Product Characteristics (SPC), Vidal, etc. | 251 (42.2%) |
Training materials provided by representatives of pharmaceutical laboratories | 238 (40.0%) |
Discussions with colleagues | 216 (36.3%) |
Professional magazines for pharmacists (e.g., Le Moniteur des pharmacies, Le quotidien du pharmacien) | 210 (35.3%) |
Personal experience | 188 (31.6%) |
French Language Pharmacy Learned Society publications | 137 (23.0%) |
Health agency recommendations (ANSM, HAS, etc.) | 130 (21.8%) |
La revue Prescrire | 73 (12.3%) |
Clinical trials found in reliable databases (Pubmed, Cochrane, Uptodate) | 51 (8.6%) |
B. Sources (used more than 50% of the time) on the best choice of NSAID ** | |
Summary of Product Characteristics (SPC), Vidal etc | 528 (88.7%) |
Health agency recommendations (ANSM, HAS, etc.) | 265 (44.5%) |
French Language Pharmacy Learned Society publications | 231 (38.8%) |
Professional magazines for pharmacists (e.g., Le Moniteur des pharmacies, Le quotidien du pharmacien) | 222 (37.3%) |
Discussions with colleagues | 178 (29.9%) |
La revue Prescrire | 113 (19.0%) |
Handbooks for both pharmacists and the general public | 101 (17.0%) |
Personal experience | 98 (16.5%) |
Clinical trials found in reliable databases (Pubmed, Cochrane, Uptodate) | 39 (6.6%) |
Training materials provided by representatives of pharmaceutical laboratories | 25 (4.2%) |
Univariate OR [95% CI] | Multivariate OR [95% CI] | |
---|---|---|
Health agency recommendations (ANSM, HAS, etc.) * | 1.33 [1.15–1.53] p < 0.01 | 1.25 [1.06–1.47] p < 0.01 |
Personal experience * | 0.85 [0.73–0.99] p = 0.041 | 0.82 [0.69–0.96] p = 0.016 |
Reading “La revue Prescrire” * | 1.29 [1.13–1.47] p < 0.01 | 1.21 [1.05–1.39] p = 0.010 |
Clinical trials found in reliable databases * | 1.29 [1.07–1.56] p < 0.01 | / |
Consulting magazines for pharmacists * | 1.23 [1.10–1.38] p < 0.01 | / |
Training materials provided by pharmaceutical laboratories ** | 0.85 [0.74–0.98] p = 0.023 | 0.83 [0.71–0.96] p = 0.012 |
Number of pharmacists in the dispensary | 1.19 [1.03–1.38] p = 0.016 | / |
Having a diploma in homeopathy | 0.49 [0.27–0.89] p = 0.020 | 0.47 [0.25–0.90] p = 0.024 |
Being male | 1.40 [0.99–1.99] p = 0.060 | 1.53 [1.04–2.25] p = 0.030 |
Pharmacist status | ||
Owner CP | 1.00 | 1.00 |
Salaried CP | 1.34 [0.93–1.94] p = 0.120 | 1.38 [0.91–2.09] p = 0.131 |
Substitute CP | 1.82 [0.82–4.00] p = 0.139 | 1.62 [0.71–3.74] p = 0.255 |
Junior CP/final year student | 3.21 [1.67–6.17] p < 0.01 | 3.07 [1.55–6.08] p < 0.01 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bosson, L.; Veyer, F.; Bardet, J.-D.; Vermorel, C.; Foote, A.; Allenet, B.; Bosson, J.-L. Evidence-Based Pharmaceutical Care in Community Pharmacies: A Survey of 595 French Pharmacists. Pharmacy 2023, 11, 161. https://doi.org/10.3390/pharmacy11050161
Bosson L, Veyer F, Bardet J-D, Vermorel C, Foote A, Allenet B, Bosson J-L. Evidence-Based Pharmaceutical Care in Community Pharmacies: A Survey of 595 French Pharmacists. Pharmacy. 2023; 11(5):161. https://doi.org/10.3390/pharmacy11050161
Chicago/Turabian StyleBosson, Louis, Francesca Veyer, Jean-Didier Bardet, Céline Vermorel, Alison Foote, Benoit Allenet, and Jean-Luc Bosson. 2023. "Evidence-Based Pharmaceutical Care in Community Pharmacies: A Survey of 595 French Pharmacists" Pharmacy 11, no. 5: 161. https://doi.org/10.3390/pharmacy11050161
APA StyleBosson, L., Veyer, F., Bardet, J. -D., Vermorel, C., Foote, A., Allenet, B., & Bosson, J. -L. (2023). Evidence-Based Pharmaceutical Care in Community Pharmacies: A Survey of 595 French Pharmacists. Pharmacy, 11(5), 161. https://doi.org/10.3390/pharmacy11050161